CY1117431T1 - 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου - Google Patents
2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινουInfo
- Publication number
- CY1117431T1 CY1117431T1 CY20161100168T CY161100168T CY1117431T1 CY 1117431 T1 CY1117431 T1 CY 1117431T1 CY 20161100168 T CY20161100168 T CY 20161100168T CY 161100168 T CY161100168 T CY 161100168T CY 1117431 T1 CY1117431 T1 CY 1117431T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- salts
- useful
- anilino
- egfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Η παρούσα εφεύρεση αναφέρεται σε συγκεκριμένες ενώσεις 2-(2,4,5-υποκατεστημένης-ανιλινο) πυριμιδίνης και σε φαρμακευτικώς αποδεκτά άλατα αυτών, που μπορεί να είναι χρήσιμα στη θεραπευτική αντιμετώπιση ή πρόληψη μίας πάθησης ή ιατρικής κατάστασης που προκαλείται από συγκεκριμένες μεταλλαγμένες μορφές του υποδοχέα του επιδερμικού αυξητικού παράγοντα (για παράδειγμα το μετάλλαγμα ενεργοποίησης L858R, το μετάλλαγμα ενεργοποίησης Exon19 διαγραφής και το ανθεκτικό μετάλλαγμα Τ790Μ). Αυτές οι ενώσεις και τα άλατα αυτών μπορεί να είναι χρήσιμα στη θεραπευτική αντιμετώπιση ή πρόληψη ενός αριθμού διαφορετικών καρκίνων. Η εφεύρεση επίσης αναφέρεται σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω ενώσεις και τα άλατα αυτών, κυρίως χρήσιμες πολυμορφικές μορφές αυτών των ενώσεων και αλάτων, ενδιάμεσες ενώσεις χρήσιμες στην παρασκευή των εν λόγω ενώσεων και σε μεθόδους θεραπευτικής αντιμετώπισης παθήσεων που προκαλούνται από διάφορες, διαφορετικές μορφές του EGFR χρησιμοποιώντας τις εν λόγω ενώσεις και τα άλατα αυτών.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161512061P | 2011-07-27 | 2011-07-27 | |
US201261591363P | 2012-01-27 | 2012-01-27 | |
EP12759801.9A EP2736895B1 (en) | 2011-07-27 | 2012-07-25 | 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117431T1 true CY1117431T1 (el) | 2017-04-26 |
Family
ID=46875901
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100168T CY1117431T1 (el) | 2011-07-27 | 2016-03-01 | 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου |
CY20181100002T CY1120072T1 (el) | 2011-07-27 | 2018-01-03 | 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου |
CY20201100434T CY1123210T1 (el) | 2011-07-27 | 2020-05-12 | 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου |
CY20211100994T CY1125405T1 (el) | 2011-07-27 | 2021-11-17 | Ενωσεις 2-(2,4,5-υποκατεστημενης-ανιλινο) πυριμιδινης |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100002T CY1120072T1 (el) | 2011-07-27 | 2018-01-03 | 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου |
CY20201100434T CY1123210T1 (el) | 2011-07-27 | 2020-05-12 | 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου |
CY20211100994T CY1125405T1 (el) | 2011-07-27 | 2021-11-17 | Ενωσεις 2-(2,4,5-υποκατεστημενης-ανιλινο) πυριμιδινης |
Country Status (39)
Country | Link |
---|---|
US (6) | US8946235B2 (el) |
EP (7) | EP3009431B1 (el) |
JP (3) | JP5427321B2 (el) |
KR (3) | KR101691268B1 (el) |
CN (7) | CN105348266B (el) |
AR (1) | AR087336A1 (el) |
AU (1) | AU2012288626C1 (el) |
BR (4) | BR122014026094B1 (el) |
CA (5) | CA2881993C (el) |
CL (1) | CL2013003281A1 (el) |
CO (1) | CO6811863A2 (el) |
CR (1) | CR20130629A (el) |
CY (4) | CY1117431T1 (el) |
DK (5) | DK3333161T3 (el) |
DO (1) | DOP2013000263A (el) |
EA (3) | EA029488B1 (el) |
EC (1) | ECSP13013033A (el) |
ES (5) | ES2914854T3 (el) |
GT (1) | GT201300288A (el) |
HK (4) | HK1192549A1 (el) |
HR (4) | HRP20211682T1 (el) |
HU (4) | HUE026429T2 (el) |
IL (6) | IL229199A (el) |
LT (3) | LT3333161T (el) |
ME (3) | ME02887B (el) |
MX (2) | MX2014000528A (el) |
MY (2) | MY161925A (el) |
NI (1) | NI201300134A (el) |
PE (1) | PE20141700A1 (el) |
PH (1) | PH12015501326B1 (el) |
PL (5) | PL3009431T3 (el) |
PT (4) | PT3686193T (el) |
RS (4) | RS54653B1 (el) |
SG (5) | SG10201910986QA (el) |
SI (4) | SI3333161T1 (el) |
SM (1) | SMT201600070B (el) |
TW (3) | TWI465445B (el) |
UY (1) | UY34219A (el) |
WO (1) | WO2013014448A1 (el) |
Families Citing this family (210)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
KR101769999B1 (ko) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Nmda 수용체 조절제 및 그의 용도 |
BR112012003955A2 (pt) | 2009-08-20 | 2017-09-26 | Karus Therapeutics Ltd | compostos heterocíclicos tricíclicos como inibidores da fosfoinositídeos 3-quinase |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
CN105348266B (zh) | 2011-07-27 | 2018-04-10 | 阿斯利康(瑞典)有限公司 | 取代的3‑氯‑n‑[3‑(嘧啶‑2‑基氨基)苯基]丙酰胺或其盐 |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
JP2016506958A (ja) | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系nmda受容体モジュレーターおよびその使用 |
CN105408336B (zh) * | 2013-01-29 | 2018-06-26 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
PT2968290T (pt) | 2013-03-15 | 2019-11-27 | G1 Therapeutics Inc | Protecção transitória de células normais durante a quimioterapia |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2014210354A1 (en) * | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
CN104292142B (zh) * | 2013-07-17 | 2019-05-14 | 天津大地康和医药技术有限公司 | 一种n-芳基杂环丁烷脱芳基方法 |
JP6559132B2 (ja) | 2013-08-23 | 2019-08-14 | ニューファーマ, インコーポレイテッド | ある特定の化学的実体、組成物および方法 |
DK3060550T3 (da) * | 2013-10-21 | 2019-07-22 | Merck Patent Gmbh | Heteroarylforbindelser som btk-inhibitorer og anvendelser deraf |
GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
RU2683276C2 (ru) * | 2014-04-04 | 2019-03-27 | Астразенека Аб | Комбинация ингибитора EGFR и ингибитора MEK для применения в лечении рака, вызванного мутировавшим NRAS |
AU2015240465B2 (en) | 2014-04-04 | 2020-02-27 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
CN106687457B (zh) * | 2014-05-13 | 2020-01-10 | 阿里亚德医药股份有限公司 | 用于激酶抑制的杂芳基化合物 |
CN111875585B (zh) * | 2014-06-12 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | 一类激酶抑制剂 |
CN110526912B (zh) | 2014-06-19 | 2023-02-14 | 武田药品工业株式会社 | 用于激酶抑制的杂芳基化合物 |
CN105254615B (zh) * | 2014-07-11 | 2017-02-22 | 杭州华东医药集团新药研究院有限公司 | 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途 |
CN105315285B (zh) * | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
CN105315259B (zh) * | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
CN104140418B (zh) * | 2014-08-15 | 2016-08-24 | 常州润诺生物科技有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物及其用途 |
CN113121575A (zh) * | 2014-08-25 | 2021-07-16 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
CN104356040A (zh) * | 2014-09-17 | 2015-02-18 | 爱斯特(成都)生物制药有限公司 | 一种1-二苯甲基-3-羟基氮杂环丁烷盐酸盐的制备方法 |
CN105461695B (zh) * | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
CN105524068B (zh) * | 2014-09-30 | 2017-11-24 | 上海海雁医药科技有限公司 | 氮杂双环衍生物、其制法与医药上的用途 |
CN105237515B (zh) * | 2014-10-10 | 2018-06-05 | 益方生物科技(上海)有限公司 | 氘代嘧啶类化合物、其制备方法、药物组合物和用途 |
CN111171000B (zh) | 2014-10-11 | 2023-09-01 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备和应用 |
PT3207035T (pt) * | 2014-10-13 | 2020-02-19 | Yuhan Corp | Compostos e composições para modular actividades da cinase do mutante de egfr |
CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技(上海)有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
EP3226869A4 (en) * | 2014-12-03 | 2018-07-18 | Auckland UniServices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
AU2015360360B2 (en) | 2014-12-11 | 2020-06-25 | Beta Pharma (Shanghai) Co., Ltd. | Substituted 2-anilinopyrimidine derivatives as EGFR modulators |
US10266517B2 (en) | 2014-12-23 | 2019-04-23 | Dana-Farber Cancer Institute, Inc. | Pyrimidines as EGFR inhibitors and methods of treating disorders |
CN104961731A (zh) * | 2015-02-05 | 2015-10-07 | 苏州晶云药物科技有限公司 | 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法 |
CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
US10947201B2 (en) | 2015-02-17 | 2021-03-16 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
TWI687420B (zh) * | 2015-04-29 | 2020-03-11 | 大陸商南京聖和藥業股份有限公司 | 稠環或三環芳基嘧啶化合物用作激酶抑制劑 |
WO2016173438A1 (zh) | 2015-04-29 | 2016-11-03 | 南京明德新药研发股份有限公司 | 稠环或三环芳基嘧啶化合物用作激酶抑制剂 |
CN104817541B (zh) * | 2015-05-11 | 2017-06-16 | 苏州东南药业股份有限公司 | 一种抗肿瘤药物的合成方法 |
JP6863901B2 (ja) * | 2015-05-13 | 2021-04-28 | アリアド ファーマシューティカルズ, インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
EP3294299A1 (en) | 2015-05-15 | 2018-03-21 | Novartis AG | Methods for treating egfr mutant cancers |
CN104910049B (zh) * | 2015-06-16 | 2016-06-29 | 苏州明锐医药科技有限公司 | Azd9291中间体及其制备方法 |
CN107835811B (zh) * | 2015-07-16 | 2019-11-08 | 正大天晴药业集团股份有限公司 | 苯胺嘧啶衍生物及其用途 |
AU2016296877B2 (en) * | 2015-07-20 | 2020-09-17 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as EGFR inhibitors and methods of treating disorders |
EP3327014A4 (en) * | 2015-07-24 | 2019-01-02 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof |
CN105001208A (zh) * | 2015-08-06 | 2015-10-28 | 南京雷科星生物技术有限公司 | 一种表皮生长因子受体egfr抑制剂及其制备方法与用途 |
GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
KR102051609B1 (ko) * | 2015-08-31 | 2019-12-03 | 우시 상량 바이오테크놀로지 씨오., 엘티디. | 2-아릴아미노피리딘, 피리미딘 또는 트리아진 유도체 및 그 제조방법과 사용 |
CN106117185B (zh) * | 2015-08-31 | 2017-11-07 | 广州必贝特医药技术有限公司 | 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用 |
CN110483485A (zh) * | 2015-09-02 | 2019-11-22 | 益方生物科技(上海)有限公司 | 嘧啶类化合物、其制备方法和医药用途 |
RU2606949C9 (ru) * | 2015-11-19 | 2018-03-14 | ЗАО "Р-Фарм" | Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака |
RU2603960C1 (ru) * | 2015-11-19 | 2016-12-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Дихлорацетат n1,n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака |
TW201718583A (zh) * | 2015-11-23 | 2017-06-01 | Nanjing Sanhome Pharmaceutical Co Ltd | 新的表皮生長因子受體抑制劑及其應用 |
CN106810553B (zh) * | 2015-11-30 | 2020-03-17 | 江苏正大丰海制药有限公司 | 3-(4,5-取代氨基嘧啶)苯基衍生物及其应用 |
CA3005751A1 (en) * | 2015-12-03 | 2017-06-08 | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. | Thieno-pyrimidine derivatives and uses thereof |
EP3383877B1 (en) * | 2015-12-03 | 2021-09-15 | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. | Heterocycle compounds and uses thereof |
CN105601620A (zh) * | 2015-12-25 | 2016-05-25 | 北京康立生医药技术开发有限公司 | 一种甲磺酸迈瑞替尼的制备方法 |
CN106928150B (zh) | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技(上海)有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
JP2019501222A (ja) | 2016-01-07 | 2019-01-17 | シーエス ファーマテック リミテッド | Egfrチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬 |
CN105646454B (zh) * | 2016-01-19 | 2018-05-08 | 浙江大学 | 含异羟肟酸片段的2-芳胺基嘧啶类衍生物及制备和应用 |
CN108610331A (zh) * | 2016-01-22 | 2018-10-02 | 焦玉奇 | 2-(2,4,5-取代苯胺)嘧啶衍生物 |
CN106995437A (zh) * | 2016-01-22 | 2017-08-01 | 齐鲁制药有限公司 | 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途 |
TWI745345B (zh) * | 2016-02-01 | 2021-11-11 | 瑞典商阿斯特捷利康公司 | 製備奧希替尼(osimertinib,azd9291)或其鹽及「azd9291苯胺」或其鹽的改良方法 |
CN107043368B (zh) * | 2016-02-05 | 2020-07-31 | 齐鲁制药有限公司 | 芳胺嘧啶化合物及其盐的结晶 |
CN107043369A (zh) * | 2016-02-06 | 2017-08-15 | 焦玉奇 | 2‑(2,4,5‑取代苯胺)嘧啶衍生物 |
CN107098887B (zh) * | 2016-02-22 | 2019-08-09 | 复旦大学 | 嘧啶类化合物 |
CN105585557B (zh) * | 2016-02-25 | 2018-06-22 | 清华大学 | 用于靶向治疗癌症的egfr抑制剂及其制备方法与应用 |
CN105777716B (zh) * | 2016-02-25 | 2018-04-10 | 清华大学 | 一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用 |
CN105646467B (zh) * | 2016-02-25 | 2018-07-20 | 黄燕鸽 | 一种抗癌化合物奥美替尼及其合成方法 |
CN107163026B (zh) | 2016-03-07 | 2019-07-02 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 |
CN107163027B (zh) | 2016-03-07 | 2019-11-05 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 |
CN107188888A (zh) * | 2016-03-15 | 2017-09-22 | 罗欣生物科技(上海)有限公司 | 一种制备甲磺酸迈瑞替尼的方法 |
CN112645933B (zh) * | 2016-03-22 | 2022-02-11 | 江苏豪森药业集团有限公司 | Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用 |
WO2017197062A1 (en) | 2016-05-11 | 2017-11-16 | Beta Pharma, Inc. | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
EA201892657A1 (ru) | 2016-05-19 | 2019-05-31 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
EP3464275B1 (en) * | 2016-05-26 | 2024-05-08 | Recurium IP Holdings, LLC | Egfr inhibitor compounds |
EA201892661A1 (ru) * | 2016-06-17 | 2019-07-31 | Бета Фарма, Инк. | Фармацевтические соли n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и их кристаллические формы |
CN107522690B (zh) * | 2016-06-20 | 2022-08-05 | 海南先声药业有限公司 | 一种Osimertinib的制备方法 |
CN107540661A (zh) * | 2016-06-24 | 2018-01-05 | 正大天晴药业集团股份有限公司 | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 |
CN107663208B (zh) * | 2016-07-27 | 2021-10-15 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途 |
CN107663207B (zh) * | 2016-07-27 | 2021-07-30 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法 |
US11299495B2 (en) | 2016-08-01 | 2022-04-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
PE20190502A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos |
CA3031563C (en) | 2016-08-01 | 2023-12-05 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
MX2019001318A (es) | 2016-08-01 | 2019-07-01 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos. |
CN109890825B (zh) | 2016-08-01 | 2022-03-11 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
EP4006035B1 (en) | 2016-08-15 | 2023-11-22 | Neupharma, Inc. | Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer |
CN106366072B (zh) * | 2016-08-19 | 2018-12-07 | 上海工程技术大学 | 一种azd9291的制备方法 |
CN106366022B (zh) * | 2016-08-19 | 2018-03-13 | 上海工程技术大学 | 一种用于制备azd9291的中间体及其制备方法和应用 |
CN106397407B (zh) * | 2016-08-31 | 2018-09-04 | 浙江科聚化工有限公司 | 抗肿瘤药物azd9291衍生物的制备方法 |
CN106432231B (zh) * | 2016-09-09 | 2018-06-12 | 无锡佰翱得生物科学有限公司 | Azd9291的药用盐、及其晶型和制备方法 |
JP6746794B2 (ja) * | 2016-09-19 | 2020-08-26 | 南京創特医薬科技有限公司Nanjing Chuangte Pharmaceutical Technology Co., Ltd | 重水素化3−(4,5−置換アミノピリミジン)フェニル誘導体及びその使用 |
CN107955019B (zh) * | 2016-10-17 | 2021-09-14 | 广东众生药业股份有限公司 | 一种egfr抑制剂的盐型、晶型及其制备方法 |
WO2018073839A1 (en) | 2016-10-18 | 2018-04-26 | Mylan Laboratories Limited | Amorphous osimertinib mesylate, processes for its preparation and solid amorphous dispersions thereof |
AU2017345574A1 (en) * | 2016-10-19 | 2019-05-23 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating cancer |
CN106496196B (zh) * | 2016-10-20 | 2019-07-02 | 南京雷科星生物技术有限公司 | 一种喹唑啉、吡啶并嘧啶或则双并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途 |
CN106543060B (zh) * | 2016-10-31 | 2018-11-06 | 湖南欧亚药业有限公司 | 一种奥斯替尼甲磺酸盐的制备方法 |
CN108299419B (zh) * | 2017-01-11 | 2022-04-26 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 |
CN110214138A (zh) | 2017-01-26 | 2019-09-06 | 韩美药品株式会社 | 嘧啶化合物及其药物用途 |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
CN110325191A (zh) * | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
TWI796326B (zh) | 2017-03-24 | 2023-03-21 | 日商第一三共股份有限公司 | 含有axl抑制劑與egfr酪胺酸激酶抑制藥的醫藥品及其用途 |
CN106883216B (zh) * | 2017-04-06 | 2020-03-13 | 张家港威胜生物医药有限公司 | 一种奥希替尼的制备方法 |
CN108503627A (zh) * | 2017-04-19 | 2018-09-07 | 郑州泰基鸿诺医药股份有限公司 | 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用 |
AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
CN106967050A (zh) * | 2017-05-11 | 2017-07-21 | 北京工业大学 | 一种azd9291的制备方法 |
CN108929311B (zh) * | 2017-05-22 | 2020-07-28 | 焦玉奇 | 2-(2,4,5-取代苯胺)嘧啶衍生物 |
US10882845B2 (en) | 2017-05-24 | 2021-01-05 | TYK Medicines Inc. | Crystal form of deuterated AZD9291, preparation method therefor, and use thereof |
CN107176954B (zh) | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
JP7028900B2 (ja) * | 2017-06-13 | 2022-03-02 | ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー | アミノピリミジン化合物、その調製方法、およびその使用 |
CN110799191B (zh) | 2017-06-16 | 2023-05-26 | 贝塔制药有限公司 | N-(2-(2-(二甲氨基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)氨基)苯基)丙烯酰胺及其盐的药物制剂 |
CN108467385A (zh) * | 2017-06-27 | 2018-08-31 | 浙江同源康医药股份有限公司 | 一种氘代奥斯替尼衍生物及其应用 |
CN107095873A (zh) * | 2017-06-28 | 2017-08-29 | 卢凯华 | 具有低耐药性的抗肺癌靶向药物组合物 |
CN107216313B (zh) * | 2017-06-29 | 2019-11-19 | 山东四环药业股份有限公司 | 一种抗肿瘤药物azd9291的制备方法 |
WO2019010619A1 (zh) * | 2017-07-10 | 2019-01-17 | 焦玉奇 | 2-(2,4,5-取代苯胺)嘧啶衍生物 |
FI3658552T3 (fi) * | 2017-07-28 | 2023-11-16 | Yuhan Corp | Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa |
PT3658547T (pt) | 2017-07-28 | 2023-10-20 | Yuhan Corp | Processo de preparação de n -(5 -(4 -(4 -formil -3- fenil- 1h -pirazol- 1 -il)pirimidin -2- ilamino) -4 -metoxi 2- morfolinofenil) acrilamida |
CN107266426A (zh) * | 2017-08-15 | 2017-10-20 | 南通因诺威医药科技有限公司 | 2‑氨烃基嘧啶类化合物及其制备方法和用途 |
WO2019040348A1 (en) | 2017-08-21 | 2019-02-28 | Eli Lilly And Company | COMBINATIONS OF EGFR INHIBITORS AND ANTI-VEGFR -2 HUMAN ANTIBODIES |
CN109485638B (zh) * | 2017-09-12 | 2020-07-17 | 新发药业有限公司 | 一种奥希替尼中间体的制备方法 |
CN107915725B (zh) * | 2017-10-20 | 2023-06-27 | 复旦大学 | Azd9291的药用盐及其制备方法 |
WO2019099873A1 (en) * | 2017-11-17 | 2019-05-23 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual mek signaling |
SG11202005937QA (en) | 2018-01-08 | 2020-07-29 | G1 Therapeutics Inc | G1t38 superior dosage regimes |
WO2019152696A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
JP7210599B2 (ja) | 2018-01-31 | 2023-01-23 | アプティニックス インコーポレイテッド | スピロラクタム系nmda受容体修飾因子およびその使用 |
CA3090528A1 (en) * | 2018-02-08 | 2019-08-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
JP2021513517A (ja) | 2018-02-12 | 2021-05-27 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
CA3088972A1 (en) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical combinations of egfr inhibitors and methods of use thereof |
AU2019225807A1 (en) * | 2018-02-20 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical combinations of EGFR inhibitors and methods of use thereof |
CN108191861B (zh) * | 2018-03-01 | 2020-10-02 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺 |
CN108250187B (zh) * | 2018-03-01 | 2021-01-05 | 中国科学院上海药物研究所 | 吲哚-1-碳酸酯类化合物、其制备方法和应用 |
WO2019175093A1 (en) | 2018-03-12 | 2019-09-19 | Astrazeneca Ab | Method for treating lung cancer |
CN109666024A (zh) * | 2018-03-20 | 2019-04-23 | 兰州大学 | 2-氧嘧啶类化合物及其制备方法和用途 |
CN108218839A (zh) * | 2018-03-20 | 2018-06-29 | 上药康丽(常州)药业有限公司 | 一种抗肿瘤药物azd9291的制备方法 |
CN108484579A (zh) * | 2018-03-28 | 2018-09-04 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成奥希替尼中间体的方法 |
CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
US11639344B2 (en) | 2018-05-15 | 2023-05-02 | InventisBio Co., Ltd. | EGFR inhibitors |
CN110606842B (zh) * | 2018-06-15 | 2021-06-01 | 上海艾力斯医药科技股份有限公司 | 吡啶胺基嘧啶衍生物的制备方法及其中间体 |
CN110698461B (zh) * | 2018-07-09 | 2024-04-05 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制备方法 |
CN109134435B (zh) * | 2018-10-29 | 2023-01-03 | 湖南大学 | 一种奥希替尼azd9291的合成方法 |
CN111233774B (zh) * | 2018-11-28 | 2023-04-14 | 鲁南制药集团股份有限公司 | 一种胺基嘧啶类化合物 |
EP3903828A4 (en) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR |
WO2020140934A1 (zh) * | 2019-01-05 | 2020-07-09 | 山东轩竹医药科技有限公司 | Egfr酪氨酸激酶的选择性抑制剂的盐及其晶型 |
CN111410651B (zh) * | 2019-01-05 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂的盐及其晶型 |
CN111606889B (zh) * | 2019-02-25 | 2023-03-07 | 上海翰森生物医药科技有限公司 | 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法 |
CN113773304B (zh) * | 2019-02-25 | 2023-03-10 | 江苏豪森药业集团有限公司 | 抗耐药抗肿瘤egfr抑制剂的制备方法 |
CN109928956B (zh) * | 2019-02-27 | 2020-10-13 | 杭州偶联医药科技有限公司 | 一种靶向泛素化降解egfr蛋白的化合物及其药物组合物和应用 |
WO2020192302A1 (zh) * | 2019-03-27 | 2020-10-01 | 广州必贝特医药技术有限公司 | 含嘧啶的三取代咪唑类化合物及其应用 |
CN111747950B (zh) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
WO2020201097A1 (en) | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
EP3954682A4 (en) * | 2019-04-09 | 2022-10-12 | Henan Genuine Biotech Co., Ltd. | 2-(2,4,5-SUBSTITUTED PHENYLAMINO)PYRIMIDINE DERIVATIVE AND CRYSTALLINE B FORM THEREOF |
CN109942550A (zh) * | 2019-04-15 | 2019-06-28 | 广州医科大学附属第一医院(广州呼吸中心) | 11c标记的egfr正电子示踪剂及其制备方法和应用 |
AU2020264808A1 (en) | 2019-05-01 | 2021-11-04 | Clexio Biosciences Ltd. | Methods of treating pruritus |
US20220340547A1 (en) * | 2019-05-22 | 2022-10-27 | Shanghi Hansoh Biosoh Biomedical Co., Ltd. | Indole derivative-containing inhibitor, preparation method therefor and application thereof |
CN110283162B (zh) * | 2019-07-09 | 2022-04-05 | 辽宁大学 | 一种表皮生长因子受体抑制剂及其应用 |
CN110483486B (zh) * | 2019-09-17 | 2024-01-26 | 鲁南制药集团股份有限公司 | 一种奥西替尼酮咯酸盐晶型及其制备方法 |
WO2021094379A1 (en) | 2019-11-12 | 2021-05-20 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2021111462A1 (en) * | 2019-12-02 | 2021-06-10 | Natco Pharma Limited | An improved process for the preparation of osimertinib mesylate |
EP4076667A1 (en) | 2019-12-20 | 2022-10-26 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
AU2021211871A1 (en) | 2020-01-20 | 2022-09-08 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
CN113372332B (zh) * | 2020-03-10 | 2023-09-12 | 鲁南制药集团股份有限公司 | 一种奥希替尼新晶型 |
CN113372331B (zh) * | 2020-03-10 | 2023-09-12 | 鲁南制药集团股份有限公司 | 一种奥希替尼一水合物新晶型 |
CN111303123B (zh) * | 2020-03-31 | 2021-08-31 | 南京雷正医药科技有限公司 | 2-(2,4,5-取代苯胺基)嘧啶化合物及其应用 |
CN111285852A (zh) * | 2020-04-02 | 2020-06-16 | 广州博济医药生物技术股份有限公司 | 氘代奥希替尼药用盐的晶型及其制备方法 |
CN111303124A (zh) * | 2020-04-08 | 2020-06-19 | 北京赛思源生物医药技术有限公司 | 一种甲磺酸奥希替尼的新晶体 |
US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
CN113801101A (zh) * | 2020-06-15 | 2021-12-17 | 鲁南制药集团股份有限公司 | Azd9291-2-酮戊二酸盐及其制备方法 |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
CN113929663A (zh) * | 2020-06-29 | 2022-01-14 | 鲁南制药集团股份有限公司 | Azd9291-2-吲哚甲酸盐及其制备方法 |
CN113929664A (zh) * | 2020-07-13 | 2022-01-14 | 鲁南制药集团股份有限公司 | Azd9291-3,5-吡啶二羧酸盐及其制备方法 |
CN113968845A (zh) * | 2020-07-24 | 2022-01-25 | 鲁南制药集团股份有限公司 | Azd9291-没食子酸盐及其制备方法 |
US20230321098A1 (en) | 2020-08-25 | 2023-10-12 | Loxo Oncology, Inc. | Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers |
CA3196277A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
CN112430231B (zh) * | 2020-11-06 | 2022-09-30 | 德州德药制药有限公司 | 一种azd9291的工业化制备方法 |
CN112358468B (zh) * | 2020-11-10 | 2022-03-22 | 德州德药制药有限公司 | 一种工业化合成azd9291的方法 |
WO2022105882A1 (zh) * | 2020-11-19 | 2022-05-27 | 上海翰森生物医药科技有限公司 | 一种含吲哚类衍生物的盐、晶型及其制备方法和应用 |
US11780824B2 (en) | 2020-12-16 | 2023-10-10 | Scinopharm Taiwan, Ltd. | Process for preparing osimertinib or a salt thereof |
US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
CN117479943A (zh) | 2021-06-15 | 2024-01-30 | 基因泰克公司 | 组合疗法中的egfr抑制剂和perk活化剂及其用于治疗癌症的用途 |
CN113387935B (zh) * | 2021-07-23 | 2022-06-10 | 苏州雅深智慧科技有限公司 | 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途 |
CA3224289A1 (en) * | 2021-08-06 | 2023-02-09 | Tao Feng | Pyrimidine or pyridine derivative, preparation method therefor, and application thereof in pharmacy |
KR20240055046A (ko) | 2021-09-02 | 2024-04-26 | 신톤 비.브이. | 오시머티닙을 제조하는 방법 |
CN113683612B (zh) * | 2021-09-07 | 2022-06-17 | 山东铂源药业股份有限公司 | 一种帕布昔利布的制备方法 |
JP2023043050A (ja) * | 2021-09-15 | 2023-03-28 | 株式会社東芝 | 新規アミン化合物、酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去 |
CN114014847B (zh) * | 2021-12-08 | 2023-11-03 | 滨州医学院 | 一种含苯并噻吩嘧啶衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
WO2023194531A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Improved process for the manufacture of osimertinib |
WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
WO2023213850A1 (en) * | 2022-05-03 | 2023-11-09 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) | Inhibitors of tau proteins |
WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
CN115650974A (zh) * | 2022-08-04 | 2023-01-31 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用 |
WO2024064091A1 (en) * | 2022-09-19 | 2024-03-28 | Advenchen Pharmaceuticals, LLC | Novel pyrimidine compound as kinase inhibitors with biological activities on egfr mutants |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
EP1154774B1 (en) | 1999-02-10 | 2005-06-22 | AstraZeneca AB | Quinazoline derivatives as angiogenesis inhibitors |
EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
US6881737B2 (en) * | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
DE602005014382D1 (de) * | 2004-12-21 | 2009-06-18 | Smithkline Beecham Corp | 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren |
GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
WO2006084058A2 (en) | 2005-02-03 | 2006-08-10 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
KR20080066069A (ko) | 2005-11-03 | 2008-07-15 | 버텍스 파마슈티칼스 인코포레이티드 | 키나제 억제제로서 유용한 아미노피리미딘 |
GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
US7807673B2 (en) * | 2005-12-05 | 2010-10-05 | Glaxosmithkline Llc | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors |
JP2009541318A (ja) * | 2006-06-22 | 2009-11-26 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
KR20090031787A (ko) * | 2006-07-21 | 2009-03-27 | 노파르티스 아게 | Jak 키나제 억제제로서의 2,4-디(아릴아미노)-피리미딘-5-카르복스아미드 화합물 |
TWI475996B (zh) | 2007-10-19 | 2015-03-11 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
KR20110025224A (ko) * | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
WO2010028236A1 (en) | 2008-09-05 | 2010-03-11 | Avila Therapeutics, Inc. | Algorithm for designing irreversible inhibitors |
WO2010042337A1 (en) | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
WO2010129053A2 (en) * | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
KR101256018B1 (ko) * | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
RU2012114902A (ru) | 2009-09-16 | 2013-10-27 | Авила Терапьютикс, Инк. | Конъюгаты и ингибиторы протеинкиназы |
JP2013509412A (ja) * | 2009-11-02 | 2013-03-14 | アボット・ラボラトリーズ | 多標的キナーゼ阻害における新規な足場としてのイミダゾピリジン類 |
US20110207736A1 (en) | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
WO2011140338A1 (en) | 2010-05-05 | 2011-11-10 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
NZ627709A (en) | 2010-06-23 | 2014-12-24 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
UY33539A (es) | 2010-08-02 | 2012-02-29 | Astrazeneca Ab | Compuestos químicos alk |
CN103501612B (zh) * | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
CN105348266B (zh) | 2011-07-27 | 2018-04-10 | 阿斯利康(瑞典)有限公司 | 取代的3‑氯‑n‑[3‑(嘧啶‑2‑基氨基)苯基]丙酰胺或其盐 |
-
2012
- 2012-07-25 CN CN201510639096.0A patent/CN105348266B/zh active Active
- 2012-07-25 RS RS20160094A patent/RS54653B1/en unknown
- 2012-07-25 EA EA201690328A patent/EA029488B1/ru not_active IP Right Cessation
- 2012-07-25 SG SG10201910986QA patent/SG10201910986QA/en unknown
- 2012-07-25 ES ES20157798T patent/ES2914854T3/es active Active
- 2012-07-25 CN CN201280033773.9A patent/CN103702990B/zh active Active
- 2012-07-25 EP EP15192658.1A patent/EP3009431B1/en active Active
- 2012-07-25 ME MEP-2017-290A patent/ME02887B/me unknown
- 2012-07-25 PT PT201577988T patent/PT3686193T/pt unknown
- 2012-07-25 EA EA201792394A patent/EA033733B1/ru unknown
- 2012-07-25 DK DK17194307.9T patent/DK3333161T3/da active
- 2012-07-25 CA CA2881993A patent/CA2881993C/en active Active
- 2012-07-25 BR BR122014026094-6A patent/BR122014026094B1/pt active IP Right Grant
- 2012-07-25 SI SI201231771T patent/SI3333161T1/sl unknown
- 2012-07-25 MY MYPI2013702541A patent/MY161925A/en unknown
- 2012-07-25 DK DK20157798.8T patent/DK3686193T3/da active
- 2012-07-25 CN CN201510507888.2A patent/CN105175396B/zh active Active
- 2012-07-25 LT LTEP17194307.9T patent/LT3333161T/lt unknown
- 2012-07-25 RS RS20171309A patent/RS56679B1/sr unknown
- 2012-07-25 SG SG10201402860QA patent/SG10201402860QA/en unknown
- 2012-07-25 SG SG10201402857QA patent/SG10201402857QA/en unknown
- 2012-07-25 PL PL15192658T patent/PL3009431T3/pl unknown
- 2012-07-25 CA CA2843109A patent/CA2843109C/en active Active
- 2012-07-25 KR KR1020147011325A patent/KR101691268B1/ko active IP Right Grant
- 2012-07-25 CN CN201510641921.0A patent/CN105198862B/zh active Active
- 2012-07-25 CN CN201510639051.3A patent/CN105254616B/zh active Active
- 2012-07-25 ES ES17194307T patent/ES2791308T3/es active Active
- 2012-07-25 ME MEP-2016-34A patent/ME02382B/me unknown
- 2012-07-25 SI SI201230455T patent/SI2736895T1/sl unknown
- 2012-07-25 PL PL20157798T patent/PL3686193T3/pl unknown
- 2012-07-25 DK DK20157927.3T patent/DK3686194T3/da active
- 2012-07-25 EP EP12759801.9A patent/EP2736895B1/en active Active
- 2012-07-25 BR BR122014026150-0A patent/BR122014026150B1/pt active IP Right Grant
- 2012-07-25 EP EP22158770.2A patent/EP4086246A1/en active Pending
- 2012-07-25 US US13/557,871 patent/US8946235B2/en active Active
- 2012-07-25 KR KR1020137003097A patent/KR101410902B1/ko active Protection Beyond IP Right Term
- 2012-07-25 EP EP20157927.3A patent/EP3686194B1/en active Active
- 2012-07-25 CA CA2881991A patent/CA2881991C/en active Active
- 2012-07-25 BR BR112014001768-9A patent/BR112014001768B1/pt active IP Right Grant
- 2012-07-25 SI SI201231167T patent/SI3009431T1/en unknown
- 2012-07-25 PE PE2013002532A patent/PE20141700A1/es active IP Right Grant
- 2012-07-25 PL PL12759801T patent/PL2736895T3/pl unknown
- 2012-07-25 HU HUE12759801A patent/HUE026429T2/en unknown
- 2012-07-25 ES ES12759801.9T patent/ES2564671T3/es active Active
- 2012-07-25 DK DK12759801.9T patent/DK2736895T3/da active
- 2012-07-25 HU HUE20157927A patent/HUE056365T2/hu unknown
- 2012-07-25 ME MEP-2020-87A patent/ME03785B/me unknown
- 2012-07-25 AU AU2012288626A patent/AU2012288626C1/en active Active
- 2012-07-25 CN CN201410287447.1A patent/CN104109151B/zh active Active
- 2012-07-25 MX MX2014000528A patent/MX2014000528A/es unknown
- 2012-07-25 EP EP17194307.9A patent/EP3333161B1/en active Active
- 2012-07-25 PT PT201579273T patent/PT3686194T/pt unknown
- 2012-07-25 EP EP22189028.8A patent/EP4119551A1/en active Pending
- 2012-07-25 SG SG2013081716A patent/SG194783A1/en unknown
- 2012-07-25 MY MYPI2019007672A patent/MY194532A/en unknown
- 2012-07-25 LT LTEP15192658.1T patent/LT3009431T/lt unknown
- 2012-07-25 SG SG10201910984XA patent/SG10201910984XA/en unknown
- 2012-07-25 ES ES20157927T patent/ES2900230T3/es active Active
- 2012-07-25 HU HUE15192658A patent/HUE037645T2/hu unknown
- 2012-07-25 CA CA2882018A patent/CA2882018C/en active Active
- 2012-07-25 DK DK15192658.1T patent/DK3009431T3/en active
- 2012-07-25 CN CN201410287156.2A patent/CN104109161B/zh active Active
- 2012-07-25 KR KR1020147008572A patent/KR101422619B1/ko active Protection Beyond IP Right Term
- 2012-07-25 JP JP2013541431A patent/JP5427321B2/ja active Active
- 2012-07-25 PT PT151926581T patent/PT3009431T/pt unknown
- 2012-07-25 ES ES15192658.1T patent/ES2654177T3/es active Active
- 2012-07-25 BR BR122014026114-4A patent/BR122014026114B1/pt active IP Right Grant
- 2012-07-25 WO PCT/GB2012/051783 patent/WO2013014448A1/en active Application Filing
- 2012-07-25 LT LTEP20157927.3T patent/LT3686194T/lt unknown
- 2012-07-25 EP EP20157798.8A patent/EP3686193B1/en active Active
- 2012-07-25 CA CA2881987A patent/CA2881987C/en active Active
- 2012-07-25 RS RS20211378A patent/RS62542B1/sr unknown
- 2012-07-25 PT PT171943079T patent/PT3333161T/pt unknown
- 2012-07-25 HU HUE17194307A patent/HUE049060T2/hu unknown
- 2012-07-25 RS RS20200459A patent/RS60190B1/sr unknown
- 2012-07-25 PL PL17194307T patent/PL3333161T3/pl unknown
- 2012-07-25 PL PL20157927T patent/PL3686194T3/pl unknown
- 2012-07-25 EA EA201391491A patent/EA024421B1/ru active Protection Beyond IP Right Term
- 2012-07-25 HR HRP20211682TT patent/HRP20211682T1/hr unknown
- 2012-07-25 SI SI201231963T patent/SI3686194T1/sl unknown
- 2012-07-26 TW TW101127018A patent/TWI465445B/zh active
- 2012-07-26 UY UY34219A patent/UY34219A/es not_active Application Discontinuation
- 2012-07-26 AR ARP120102716 patent/AR087336A1/es active IP Right Grant
- 2012-07-26 TW TW105130486A patent/TWI583386B/zh active
- 2012-07-26 TW TW103124452A patent/TWI555743B/zh active
-
2013
- 2013-06-05 JP JP2013118744A patent/JP5537704B2/ja active Active
- 2013-10-31 IL IL229199A patent/IL229199A/en active IP Right Grant
- 2013-11-13 DO DO2013000263A patent/DOP2013000263A/es unknown
- 2013-11-14 CL CL2013003281A patent/CL2013003281A1/es unknown
- 2013-11-19 EC ECSP13013033 patent/ECSP13013033A/es unknown
- 2013-11-20 GT GT201300288A patent/GT201300288A/es unknown
- 2013-11-28 CO CO13279940A patent/CO6811863A2/es active IP Right Grant
- 2013-11-29 CR CR20130629A patent/CR20130629A/es unknown
- 2013-12-06 NI NI201300134A patent/NI201300134A/es unknown
-
2014
- 2014-01-10 MX MX2020013020A patent/MX2020013020A/es unknown
- 2014-03-31 JP JP2014071530A patent/JP5977779B2/ja active Active
- 2014-06-18 HK HK14105766.5A patent/HK1192549A1/zh unknown
- 2014-06-19 HK HK14105842.3A patent/HK1192554A1/xx unknown
- 2014-12-19 US US14/576,721 patent/US9732058B2/en active Active
-
2015
- 2015-06-15 PH PH12015501326A patent/PH12015501326B1/en unknown
- 2015-10-26 IL IL242285A patent/IL242285A/en active IP Right Grant
- 2015-10-26 IL IL242279A patent/IL242279A/en active IP Right Grant
- 2015-10-26 IL IL242284A patent/IL242284A/en active IP Right Grant
- 2015-10-26 IL IL242286A patent/IL242286A/en active IP Right Grant
- 2015-10-26 IL IL242278A patent/IL242278A/en active IP Right Grant
-
2016
- 2016-02-05 HR HRP20160135TT patent/HRP20160135T1/hr unknown
- 2016-03-01 CY CY20161100168T patent/CY1117431T1/el unknown
- 2016-03-10 SM SM201600070T patent/SMT201600070B/xx unknown
- 2016-08-03 HK HK16109232.1A patent/HK1221216A1/zh unknown
-
2017
- 2017-07-13 US US15/649,068 patent/US10017493B2/en active Active
- 2017-12-18 HR HRP20171957TT patent/HRP20171957T1/hr unknown
-
2018
- 2018-01-03 CY CY20181100002T patent/CY1120072T1/el unknown
- 2018-05-29 US US15/991,578 patent/US20190092746A1/en not_active Abandoned
- 2018-12-04 HK HK18115460.9A patent/HK1256370A1/zh unknown
-
2019
- 2019-06-19 US US16/445,709 patent/US10858336B2/en active Active
-
2020
- 2020-04-20 HR HRP20200624TT patent/HRP20200624T1/hr unknown
- 2020-05-12 CY CY20201100434T patent/CY1123210T1/el unknown
- 2020-11-12 US US17/096,167 patent/US11524951B2/en active Active
-
2021
- 2021-11-17 CY CY20211100994T patent/CY1125405T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120072T1 (el) | 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1124359T1 (el) | Ενωσεις και συνθεσεις για ρυθμιση δραστικοτητων κινασης μεταλλακτικου egfr | |
CY1124622T1 (el) | Μεθοδοι θεραπειας του καρκινου με τη χρηση 3-(4-((4-(μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο- 2,6-διονης | |
CY1120073T1 (el) | Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2 | |
CY1123991T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CY1124680T1 (el) | Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου | |
CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1119487T1 (el) | Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα | |
CY1118135T1 (el) | Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson | |
MX2018000777A (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c. | |
CY1119727T1 (el) | Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων | |
EA201291220A1 (ru) | Производные аминопиримидина в качестве модуляторов lrrk2 | |
CY1117584T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 | |
CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
MX2012013206A (es) | Inhibidores de quinasa biciclica fusionada. | |
CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1117504T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1 | |
CY1123494T1 (el) | Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2 | |
CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
CY1120608T1 (el) | Φαρμακευτικως δραστικες ενωσεις | |
CY1123185T1 (el) | Παραγωγα ινδολιου | |
EA201990482A1 (ru) | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака | |
UA108954C2 (xx) | Сполуки 2-(2,4,5-заміщеного аніліно)піримідину | |
JOP20160150B1 (ar) | مركبات كينازولين مستبدلة وطرق استعمالها | |
CY1116744T1 (el) | Παραγωγα υποκατεστημενης ξανθινης |